Citigroup’s Immune Design Corp. IMDZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-8,412
| Closed | -$49K | – | 8004 |
|
|
2019
Q1 | $49K | Sell |
8,412
-616
| -7% | -$2.1K | ﹤0.01% | 6365 |
|
|
2018
Q4 | $12K | Sell |
9,028
-253
| -3% | -$440 | ﹤0.01% | 7107 |
|
|
2018
Q3 | $32K | Buy |
9,281
+2,744
| +42% | +$10.3K | ﹤0.01% | 6863 |
|
|
2018
Q2 | $30K | Buy |
6,537
+1,284
| +24% | +$5.12K | ﹤0.01% | 6704 |
|
|
2018
Q1 | $17K | Buy |
5,253
+695
| +15% | +$2.46K | ﹤0.01% | 6848 |
|
|
2017
Q4 | $18K | Buy |
4,558
+4,527
| +14,603% | +$24.7K | ﹤0.01% | 6801 |
|
|
2017
Q3 | $0 | Sell |
31
-83
| -73% | -$817 | ﹤0.01% | 7711 |
|
|
2017
Q2 | $1K | Sell |
114
-15
| -12% | -$105 | ﹤0.01% | 7308 |
|
|
2017
Q1 | $1K | Buy |
129
+119
| +1,190% | +$688 | ﹤0.01% | 7155 |
|
|
2016
Q4 | $0 | Buy |
+10
| New | +$71 | ﹤0.01% | 7533 |
|
|
2016
Q3 | – | Sell |
-215
| Closed | -$2K | – | 7430 |
|
|
2016
Q2 | $2K | Sell |
215
-7,729
| -97% | -$96.4K | ﹤0.01% | 6958 |
|
|
2016
Q1 | $103K | Buy |
7,944
+3,383
| +74% | +$39.1K | ﹤0.01% | 5645 |
|
|
2015
Q4 | $92K | Buy |
4,561
+4,559
| +227,950% | +$78.6K | ﹤0.01% | 5442 |
|
|
2015
Q3 | $0 | Sell |
2
-150
| -99% | -$2.81K | ﹤0.01% | 8326 |
|
|
2015
Q2 | $3K | Sell |
152
-180
| -54% | -$4.25K | ﹤0.01% | 7088 |
|
|
2015
Q1 | $7K | Sell |
332
-712
| -68% | -$18.6K | ﹤0.01% | 6642 |
|
|
2014
Q4 | $32K | Buy |
1,044
+832
| +392% | +$23.1K | ﹤0.01% | 5980 |
|
|
2014
Q3 | $4K | Buy |
+212
| New | +$2.68K | ﹤0.01% | 6707 |
|
Citigroup's IMDZ Position: Q2 2019 in Review
Citigroup sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 8,412 shares — an estimated $49K sold.
Citigroup first reported a position in IMDZ in Q3 2014 and held it in 18 quarters. The position peaked at $103K in Q1 2016. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.
- Citigroup reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
- Citigroup sold 8,412 Immune Design Corp. shares in Q2 2019, an estimated $49K.
- Citigroup first reported a position in Immune Design Corp. in Q3 2014 and held it in 18 quarters.
- Citigroup's Immune Design Corp. position peaked at $103K in Q1 2016.
- 0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.
Based on Citigroup's 13F filing for Q2 2019, filed 12 Aug 2019.